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Although colorectal cancer is a preventable and curable disease if early stage tumors are 
removed, it still represents the second cause of cancer-related death worldwide. Surgical 
resection is the only curative treatment but once operated the patient is either subjected 
to adjuvant chemotherapy or not, depending on the invasiveness of the cancer and risks 
of recurrence. In this context, we investigated, by mass spectrometry (MS), alterations in 
the repertoire of glycosylation of mucins from colorectal tumors of various stages, grades, 
and recurrence status. Tumors were also compared with their counterparts in resection 
margins from the same patients and with healthy controls. The obtained data showed 
an important decrease in the level of expression of sialylated core 3-based O-glycans 
in tumors correlated with an increase in sialylated core 1 structures. No correlation was 
established between stages of the tumor samples and mucin O-glycosylation. However, 
with the notable exception of sialyl Tn antigens, tumors with recurrence presented a 
milder alteration of glycosylation profile than tumors without recurrence. These results 
suggest that mucin O-glycans from tumors with recurrence might mimic a healthier 
physiological situation, hence deceiving the immune defense system.
Keywords: colorectal cancer, recurrence, glycosylation, human intestinal mucins, prognosis
introduction
Colorectal cancer (CRC) is the second leading cause of cancer-related death in the Western world (1). 
It arises as the result of an accumulation of genetic and epigenetic alterations leading to transforma-
tion of normal colonic epithelium to invasive adenocarcinomas, due to disorders in cell proliferation 
and differentiation (2).
Unlike many other malignancies, CRC is a preventable and curable disease if early stage tumors 
are removed. Actually surgical resection complemented or not with adjuvant chemotherapy is the 
only curative treatment. However, patient survival is highly dependent on the tumor stage at the 
Abbreviations: CID, collision-induced-dissociation; CRC, colorectal cancer; CsCl, cesium chloride; PAS, periodic acid-Schiff
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time of diagnosis. Metastatic CRC is frequently associated with 
recurrences within 5 years after surgery. In this context, there is 
an urgent need to identify biomarkers for early detection of CRC, 
to follow tumor development during the course of therapy and to 
predict recurrence.
Screening of risk populations currently remains based on fecal 
occult blood test and on colonoscopy for the possible discovery 
of polyps and invasive tumors. Despite the accuracy of these 
diagnostic methods, many CRC remain undetected until they 
have spread to the surrounding organs or lymph, correlating 
with poor prognosis because of the low sensitivity and specificity 
of these tests (3). Knowledge of the molecular mechanisms of 
colorectal carcinogenesis will help to improve tumor detection 
as well as treatment.
Altered glycosylation is a universal hallmark of cancer (4, 5). 
Many tumor-associated antigens defined by monoclonal anti-
bodies raised against cancer cells are cell-surface carbohydrate 
epitopes (6, 7). Among all glycoproteins, mucins, the major com-
ponent of the mucus gel covering and protecting the intestinal 
tract, are frequently altered in colon cancers. Alterations of mucin 
O-glycosylation include expression of relatively short truncated 
O-glycans and altered peripheral structures (8–13). Three types 
of alterations can lead to tumor-associated O-glycans: (i) neo-
expression of antigens that are not expressed in embryonic or 
healthy tissues; (ii) expression of oncofetal antigens that are absent 
or rare in healthy adult tissues but expressed during embryonic 
development; and (iii) modified expression levels of antigens 
found in healthy tissues. All these alterations are important in 
tumor biology and can be useful in clinical management (14). In 
CRC, alterations of mucin O-glycans include reduced expression 
of core 3 (GlcNAcβ1-3GalNAcα-Ser/Thr) and core 4 [GlcNAcβ1-
3(GlcNAcβ1-6)GalNAcα-Ser/Thr] based glycans (15, 16). Other 
features are an increased sialylation of mucin O-glycans and a 
decreased sulfation (13, 17, 18). We have previously described the 
increased expression of a core 3 disialyl-Lewisx glycan in colorec-
tal tumors, competing with its sulfo sialyl-Lewisx counterpart in 
normal tissue (19).
Biosynthesis of mucin O-glycans is governed by several 
glycosyltransferases. It has been shown that during malignant 
transformation the level of expression of genes encoding 
glycosyltransferases as well as activities and Golgi localiza-
tion of these enzymes are modified, leading to less complex 
structures or novel glycans (16, 20, 21). Overexpression of 
core 1 β1,3 galactosyltransferase (core 1 synthase) is associ-
ated with tumor growth and metastasis of colon cancer cells 
and with poor survival (22). Downregulation of core 2 β1,6 
N-acetylglucosaminyltransferase (core 2 synthase)  and β1,3 
N-acetylglucosaminyltransferase 6 (core 3 synthase) may be 
involved in maintaining the tumor phenotype (15, 21, 23–25).
The changes observed in colorectal cancer at the mucin 
O-glycosylation level reflect the alterations of gene expression of 
glycosyltransferases involved in their biosynthesis. Nevertheless, 
the accumulation of a given structure does not necessarily indi-
cate which glycosyltransferase gene is altered. Indeed, multiple 
changes can lead to the accumulation of specific structures. For 
instance, it has been shown that sialyl-Lewisx motifs accumula-
tion can result either from an absence of sulfation of the type 1 
chain Galβ1-3GlcNAc allowing its sialylation or from an absence 
of α2-6 sialylation of the core GalNAc that is replaced by the 
synthesis of the type 2 chain Galβ1-4GlcNAc further sialylated to 
form sialyl Lewisx motifs (26).
However, despite all these studies, many of the efforts focused 
on differential glycosylation of mucins on tumor detection and 
therapeutics remain investigative. Thus, in this work, we explored 
the differential expression of mucins and the expression level of 
the major O-glycans. The objective was to identify differences in 
mucin glycosylation between CRC of various stages and grades 
in order to propose new predictive or prognostic biomarkers in 
colon cancer.
results
cancer-associated alterations in Mucin 
O-glycosylation are not restricted to the  
Tumor but spread in resection Margins
To investigate potential differences in the profile of glycosylation 
of colon mucins during malignant transformation, colorectal 
tumor tissues were collected from 10 patients with tumors of dif-
ferent stages and grades (Table 1). Resection margins from the 
same patients were included in this study as well as five control 
mucosae from healthy individuals.
Purified mucins were analyzed for their glycan compositions 
and sequences. Oligosaccharides were released by base/borohy-
dride treatment followed by desalting. The pool of oligosaccharide 
alditols obtained from each sample was thus permethylated before 
analysis by matrix-assisted laser desorption ionization–time of 
TaBle 1 | characteristics of the tumor samples (and their paired resection margins) used in this study.
Patient age gender Tumor stage location Differentiation recurrence
1 46 Female III Right Poor No
2 55 Male II Right Moderate No
3 97 Female II Transverse Moderate Yes
4 69 Male IV Right Moderate Yes
5 64 Female II Transverse Moderate No
6 67 Male II Right Well No
7 82 Male III Left Moderate Yes
8 80 Female IV Right Poor No follow-up
9 62 Male III Sigmoid Moderate No
10 67 Male IV Left Mucinous No
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flight (MALDI-TOF) tandem MS and nano ESI Q-TOF MS/
MS as previously published (27–29). The relative abundance of 
oligosaccharides was calculated based on integration of peaks on 
MS spectra.
As shown in Figure  1 and Table  2, more than 60 ions cor-
responding to O-glycans carried by mucins were identified in 
this study. The O-glycans were 2–10 residues long and were 
mostly sialylated. Tumors presented the highest diversity, only 
one of the structure identified here being absent in these samples 
whereas 16 of them were absent in healthy controls and 11 in 
resection margins. Most of the oligosaccharides recovered in 
healthy mucosae were based on a sialylated core 3 structure 
[GlcNAcβ1-3(NeuAcα2-6)GalNAcol], as described previously 
(19, 30). For example, expression of this trisaccharide on MS 
spectra, corresponding to the ion at m/z 936, represented around 
30% of total glycans in healthy mucosae. A decreasing gradient of 
structures based on a core 3 was observed from healthy mucosae 
to tumoral samples, correlating with an increasing gradient of 
expression of structures based on a core 1 (Galβ1-3GalNAcol). 
Core 3-based O-glycans represented 64% of the O-glycans 
population in healthy mucosae, 56.5% in resection margins and 
only 27.5% of total O-glycans in tumors. The trisaccharidic core 
3 structure detected via the ion at m/z 936 dropped from 31% 
in healthy mucosa to 12% in the tumor. On the contrary, core 1 
oligosaccharides ranged from 13% in healthy mucosae to 21% 
in resection margins and 41% in tumors. Levels of expression of 
core 1 and core 3 between controls and tumors were significantly 
different (p-value of 0.0038 and 0.0062, respectively).
Among the 60 O-glycans identified, around one-third followed 
either a decreasing gradient of expression or an increasing gradient 
from healthy controls to resection margins and tumors (Figure 2). 
A decrease in the level of expression of sialylated core 3 structures 
at m/z 936, 1,140, and 1,314 was observed in tumors compared 
to resection margins and controls, the relative percentage of these 
three O-glycans was 18, 36, and 46% of total glycans, respectively. 
An increased level of expression of sialylated core 1 structures 
seemed to correlate with the decrease of core 3 glycans, the relative 
percentage of ions at m/z 895, 1,344, 1,518, and 1,793 corresponded 
to 7% in controls, 12% in resection margins, and 21% in tumors.
As previously described (19), an increase in the disialyl-Lewisx 
antigen at m/z 1,675 was observed in the tumor samples (9.4% 
of total O-glycans) compared to resection margins (2.5%) and 
controls (3.3%). Its 6-sulfo sialyl-Lewisx counterpart decreased 
in tumors (0.8% of total glycans) compared to resection margins 
(3.2%) and controls (7.1%). Other significant differences between 
tumors and controls concerned the important increase in the 
level of expression of ions at m/z 534 (from 1 in controls to 5.6% 
in tumors); 983 (from 1.6 to 7.5%); 1,344 (from 1.1 to 7.5%); and 
1,705 (from 0.6 to 3.2%). Interestingly, all these core 1-based 
glycans seem to follow the same biosynthetic pathway sequence: 
the T antigen at m/z 534 is first elongated by a GlcNAc residue to 
give the ion at m/z 779. A galactose residue is then linked to the 
GlcNAc residue to give the ion at m/z 983, which will further be 
substituted by one sialic acid residue (to give the ion at m/z 1344) 
or two sialic acid residues, giving the ion at m/z 1705.
The total sialylation level of mucin O-glycans did not sig-




FigUre 1 | structural characterization of human colorectal mucins 
O-glycans. MALDI-MS spectra, acquired in the positive ion mode [M + Na]+ 
(or [M + 2Na-H]+ for sulfated species), of human intestinal permethylated 
O-glycans from mucins purified from (a) healthy colon controls; (B) resection 
margins; (c) paired tumoral tissue. Monosaccharide symbols according to 
the Consortium for Functional Glycomics (CFG) nomenclature. Key: fucose 
(red triangle), GlcNAc (blue square), sialic acid (purple diamond), galactose 
(yellow circle), GalNAcol (yellow square), and sulfate residue (S).
TaBle 2 | Proposed neutral and acidic oligosaccharide structures or sequences identified in human mucins from tumors and resection margins 
of patients with colorectal cancers and from colonic mucosa of healthy individuals.
Proposed structures or  
sequences of oligosaccharides
[M + na]+ or [M + 2na-h]+ 
for sulfated species
Tumors resection margins healthy controls
534 5.6 ± 5.7 1.8 ± 2.1 1.0 ± 1.4
575 1.7 ± 1.5 5.8 ± 6.7 3.8 ± 2.5
663 0.2 ± 0.4 0.3 ± 0.6 1.0 ± 1.4
691 7.1 ± 7.1 5.2 ± 5.3 5.8 ± 4.9
708 0.5 ± 1 0.3 ± 0.6 0.4 ± 0.5
749 0.4 ± 0.8 1.0 ± 2.2 0
779 4.2 ± 1.5 5.0 ± 3.8 5.6 ± 0.4
867 0.8 ± 1.1 0.3 ± 0.6 0
895 10.9 ± 3.6 7.7 ± 4.2 5.7 ± 0.6
908 0.6 ± 1.0 1.3 ± 1.8 0.8 ± 1.1
936 12.1 ± 11.2 24.2 ± 10.2 30.8 ± 11.6
953 1.4 ± 0.6 3.0 ± 1.8 1.9 ± 0.7
983 7.5 ± 8.3 2.0 ± 0.7 1.6 ± 0.3
1,024 0.2 ± 0.4 0.4 ± 0.5 0.3 ± 0.5
1,041 0.0 ± 0.1 0.3 ± 0.6 0.2 ± 0.2
1,069 0.2 ± 0.4 0.2 ± 0.4 0.8 ± 0.1
1,071 0.6 ± 1.5 0 0
(Continued)
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Proposed structures or  
sequences of oligosaccharides
[M + na]+ or [M + 2na-h]+ 
for sulfated species
Tumors resection margins healthy controls
1,110 0.3 ± 0.5 0.7 ± 1.1 0.7
1,112 0.1 ± 0.2 0.2 ± 0.3 0.3 ± 0.4
1,127 0 0.3 ± 0.8 0
1,140 2.9 ± 2.8 4.4 ± 1.9 7.0
1,157 1.9 ± 1.2 0.4 ± 0.7 0.3 ± 0.4
1,198 0.0 ± 0.1 0.4 ± 0.6 0
1,228 0.8 ± 0.5 0.5 ± 0.5 0.6 ± 0.2
1,256 3.5 ± 1.8 2.7 ± 4.0 1.5 ± 0.4
1,314 3.3 ± 2.4 7.0 ± 4.3 8.0 ± 1.4
1,331 0.1 ± 0.3 0.1 ± 0.4 0.1 ± 0.2
1,344 7.5 ± 5.5 3.3 ± 6.0 1.1 ± 0.4
1,385 0.7 ± 1.4 1.9 ± 2.3 0.7 ± 1.0
1,402 0.8 ± 0.6 3.2 ± 1.4 7.1 ± 0.3
3 Hex, 2 HexNAc, GalNAcol 1,432 0.9 ± 0.8 0.2 ± 0.2 0.2 ± 0.3
2 Hex, 3 HexNAc, GalNAcol 1,473 0.1 ± 0.2 0.1 ± 0.2 0.2 ± 0.3
(Continued)
TaBle 2 | continued
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Proposed structures or  
sequences of oligosaccharides
[M + na]+ or [M + 2na-h]+ 
for sulfated species
Tumors resection margins healthy controls
1,488 0.3 ± 0.6 0.8 ± 1.7 0.7 ± 1.0
2 Hex, 2 HexNAc, 1 Fuc,  
1 SO3, GalNAcol
1,490 0.2 ± 0.4 0 0
1,501 0.5 ± 0.6 0.6 ± 0.9 1.6 ± 0.7
1,518 1.7 ± 1.8 0.4 ± 0.6 0.2 ± 0.4
1,559 0.1 ± 0.2 0.1 ± 0.2 0.1 ± 0.2
2 Hex, 2 HexNAc, 2 Fuc, GalNAcol 1,576 0 ± 0.1 0 0.1 ± 0.2
1,589 0.3 ± 0.3 0.3 ± 0.5 0.4 ± 0.1
3 Hex, 2 HexNAc, 1 Fuc, GalNAcol 1,606 0.7 ± 0.8 0 0.1 ± 0.1
2 Hex, 3 HexNAc, 1 Fuc, GalNAcol 1,647 0.6 ± 0.8 0.2 ± 0.4 0.3
1,675 9.4 ± 1.2 2.5 ± 2.4 3.3 ± 0.7
3 Hex, 3 HexNAc, GalNAcol 1,677 1.0 ± 1.3 0.4 ± 1 0
1,705 3.2 ± 3.4 2.5 ± 6.0 0.6 ± 0.1
1,718 0.2 ± 0.3 0.1 ± 0.3 0.1 ± 0.1
1,746 0.9 ± 2 1.9 ± 2.3 1.1 ± 1.5
2 Hex, 2 HexNAc, 1 Fuc, 1 NeuAc, 
GalNAcol 
1,763 0.2 ± 0.2 0.2 ± 0.3 0.3 ± 0.1
3 Hex, 2 HexNAc, 2 Fuc, GalNAcol 1,780 0.5 ± 0.8 0 0
TaBle 2 | continued
(Continued)
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Proposed structures or  
sequences of oligosaccharides
[M + na]+ or [M + 2na-h]+ 
for sulfated species
Tumors resection margins healthy controls
1,793 0.3 ± 0.4 0.2 ± 0.4 0
2 Hex, 3 HexNAc, 1 NeuAc, GalNAcol 1,834 0.1 ± 0.1 0.2 ± 0.3 0.1 ± 0.1
3 Hex, 3 HexNAc, 1 Fuc, GalNAcol 1,851 0.4 ± 0.8 0 0.1 ± 0.1
1,879 0.2 ± 0.5 0.3 ± 0.8 0
4 Hex, 3 HexNAc, GalNAcol 1,881 0.4 ± 0.7 0 0
4 Hex, 2 HexNAc, 1 Fuc, 1 SO3, 
GalNAcol
1,898 0 ± 0.1 0.1 ± 0.2 0
3 Hex, 4 HexNAc, GalNAcol 1,922 0.2 ± 0.5 0.1 ± 0.3 0.1 ± 0.1
2 Hex, 2 HexNAc, 2 Fuc, 1 NeuAc, 
GalNAcol
1,937 0 ± 0.1 0 0.1 ± 0.1
3 Hex, 3 HexNAc, 1 Fuc, 1 SO3, 
GalNAcol
1,939 0.1 ± 0.2 0 0
3 Hex, 2 HexNAc, 3 Fuc, GalNAcol 1,954 0.1 ± 0.2 0 0
4 Hex, 2 HexNAc, 1 NeuAc, GalNAcol 1,997 0.1 ± 0.2 0 0
3 Hex, 3 HexNAc, 2 Fuc, GalNAcol 2,025 0.4 ± 0.5 0.1 ± 0.2 0.1 ± 0.1
5 Hex, 3 HexNAc, GalNAcol 2,055 0.6 ± 0.9 0 0
The relative percentage of each oligosaccharide was calculated based on the integration of peaks on MS spectra. Results are presented as the mean ± SD of percentage of each 
oligosaccharide for a same condition.
Monosaccharide symbols according to the Consortium for Functional Glycomics (CFG) nomenclature. Key: fucose (red triangle), GlcNAc (blue square), sialic acid (purple diamond), 
galactose (yellow circle), GalNAcol (yellow square), and sulfate residue (S).
TaBle 2 | continued
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controls and represented 67, 71, and 78% of total O-glycans, 
respectively. A decrease in the level of sulfation was observed in 
tumors (only 3.4% of total oligosaccharides) compared to resec-
tion margins (5.7%) and controls (9.4%).
Generally, the levels observed for the resection margins are 
intermediate between the situation in healthy mucosa and 
what is observed in tumors. It has been shown that inflamma-
tion can affect the O-glycosylation profile, for instance, in the 
case of acute ulcerative colitis (31). Micro-inflammation could 
therefore explain the observed glycosylation pattern of resection 
margins. SD values (Table 2) indicated that levels of expression 
of oligosaccharides from tumors showed more heterogeneity 
and inter-individual variations than those from healthy controls. 
This result may be explained by the fact that tumoral samples 
presented different anatomo-pathological features such as degree 
of histological differentiation or tumoral stage.
comparison of the repertoire of glycosylation 
of Mucin O-glycans according  
to the Tumor stage
Colorectal cancers are most commonly classified using the TNM 
staging system. This system takes into account three key factors 
that are the invasiveness of the tumor (T), lymph nodes (N), and 
metastasis (M). Once the T, N, and M scores have been assigned 
(each of three factors are assigned either with a number 0–4 for 
T or 0–1 for N and M), an overall stage is determined, and thus 
treatment options may be proposed and explored. In stage 0, 
the cancer has not grown beyond the inner layer of the colon 
or rectum. In stage I, the cancer has grown into the submucosa 
and muscularis propria whereas in stage II the cancer has grown 
through all the layers of the colon or rectum with or without the 
perforation of visceral peritoneum. In stage IIc, the cancer has 
also grown into nearby organs or tissues, in contrast to stage IIb. 
Stage III is divided into three categories, depending on the extent 
to which the cancer has spread, and how many lymph nodes have 
been affected. Stage IV is the most advanced stage of colorectal 
cancers; it has metastasized to distant sites such as the liver or the 
lung. The cancer may or may not have grown through the wall 
of the colon or rectum, and lymph nodes may or may not have 
been affected.
In this study, four patients presented a cancer of stage II, three 
were of stage III, and three of stage IV. Compared to stages II and 
III, stage IV was characterized by a low increase in the level of 
expression of three ions: the ion at m/z 534, corresponding to the 
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T antigen represented 7.1% of total O-glycans in stage II to 1.2% 
in stage III and 9.7% in stage IV (Figure 3). The ion at m/z 691, 
corresponding to the sialyl Tn antigen increased from 5.9% of 
total O-glycans in stage II, 6% in stage III, and 10.7% in stage IV. 
The level of expression of the last ion at m/z 983, corresponding to 
a core 1 tetrasaccharide was 6% of total glycans in stage II, 3.9% in 
stage III, and 15.1% in stage IV. However, no direct link between 
carcinogenesis stages and O-glycans structure profile could be 
drawn from these results.
Tumors with recurrence can be Distinguished 
from Tumors Without recurrence
In this study, all patients underwent curative resection for colo-
rectal cancers. The profiles of mucin O-glycans released from 
tumors with recurrence and from tumors without recurrence 
were compared and confronted to the dataset from healthy con-
trols. Figures 4 and 5 highlight differences between samples in 
the level of expression of oligosaccharides. Three kinds of differ-
ences could be identified: ions at m/z 534, 983, 1,157, 1,344, and 
1,705, all corresponding to core 1 glycans, showed an increasing 
gradient of expression from healthy controls to tumors without 
recurrence. Tumors with recurrence presented an intermediate 
level of expression of these glycans.
On the contrary, ions at m/z 936, 1,140, and 1,314, all corre-
sponding to sialylated core 3 glycans, showed a decreasing gradi-
ent of expression from controls to tumors without recurrence, 
with again an intermediate state for tumors with recurrences.
The last kind of differences concerned sialyl Tn, sialyl T, and 
disialyl T antigens at m/z 691, 895, and 1,256, respectively. Each 
of these three antigens was more expressed in tumors with recur-
rence than in tumors without recurrence and healthy controls. 
The levels of expression of sialyl Tn antigen between the two types 
of tumors were significantly different (p = 0.012).
Discussion
Colorectal cancer is the third most commonly diagnosed cancer 
in males and the second in females, with over 1.2 million new 
cases and around 600,000 deaths estimated to have occurred 
worldwide in 2008 (32). Surgical resection is the primary treat-
ment modality for stages I–III CRC, and the most powerful tool 
for assessing prognosis following curative surgery remains patho-
logic analysis of the resected specimen. Currently, the parameters 
that determine pathologic stage are the strongest predictors of 
postoperative outcome. An intensive surveillance for patients 
with resected cancer is highly recommended, and is based on 
a clinical encounter with a physician every 3–6 months for the 
first 3 years and serial measurement of carcinoembryonic anti-
gen (CEA) at each follow-up visit. However, approximately one 
in three people who develop CRC dies of this disease and more 
than 40% will have a disease recurrence, despite development of 
screening tests and surveillance for CRC in patients with colon 
polyps and/or family history and despite progress in surgical 
resection of tumors, adjuvant chemotherapy, and postoperative 
surveillance. Therefore, the challenge is to identify new cancer 
markers for prediction of the risk of recurrence after potentially 
curative resection.
Aberrant expression and glycosylation of mucins is a com-
mon feature of all adenocarcinomas (14, 33, 34). In colorectal 
cancer, the differences from normal mucins have been described 
both at the gene and post-translational levels. The synthesis of 
MUC2,  the main intestinal secreted mucins, has been shown 
to be suppressed in colorectal cancer and its metastases (35). 
Distribution of MUC2 within goblet cells changes in adenomas 
compared to healthy mucosa, with, for example, an increased 
presence in the cytoplasm and Golgi apparatus and a decreased 
localization in the vesicle (36). A de novo expression of MUC5AC, 
a gastric foveolar mucin has been described in mucinous 
adenocarcinomas as well as in tumors exhibiting microsatellite 
instability (37–39). MUC5AC and MUC6 were also found in a 
high proportion of villous and tubulovillous adenomas but not in 
normal colonic biopsies (40). No significant association between 
A
B
FigUre 2 | gradients in the level of expression of mucin O-glycans 
from healthy controls colonic tissues (n = 5) to resection margins 
(n = 10) and paired tumors of patients (n = 10) with colorectal 
cancers. The mean is represented for all measurements. (a) CRC-specific 
increase in the level of expression of O-glycans corresponding to ions at m/z 
534, 895, 983, 1,157, 1,256, 1,344, 1,518, and 1,705. (B) CRC-specific 
decrease in the level of expression of O-glycans corresponding to ions at m/z 
663, 779, 936, 1,112, 1,140, 1,314, and 1,402.
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high mucin content in colorectal cancer and overall survival or 
celerity of disease progression has yet been demonstrated (41).
Alterations of mucin glycosylation in colorectal cancer include 
reduced number and length of carbohydrate side chains on apomu-
cins, deletion of normally expressed antigens, de novo appearance 
of novel antigens, and expression of blood group-incompatible 
antigens (20, 33, 34, 42). Although mucin O-glycans have long 
been implicated in colorectal carcinogenesis, none of them have 
been explored as potential marker of recurrence. In this study, 
we compared the O-glycosylation profile of mucins from tumors 
with or without recurrence and have observed important differ-
ences in the level of expression of O-glycans between these two 
types of samples.
First of all, the level of expression of sialyl Tn antigens at m/z 
691 is significantly higher in tumors with recurrence, compared 
to tumors without recurrence. This result is in agreement with 
previous studies demonstrating that overexpression of Tn and 
sialyl Tn antigens are characteristics of more advanced and poorly 
differentiated colon cancers (8, 43). In a recent study conducted by 
Chik et al., overexpression of sialyl Tn antigens was correlated with 
upregulation of alpha 2,6 sialyltransferase gene (ST6GALNAC1) 
and a decrease in core 1 synthase gene (C1GALT1) in the mucinous 
colorectal cancer cell line LS174T (44). Interestingly, our analysis 
of mucin glycosylation of tumors with recurrence demonstrated a 
higher proportion of core 3 O-glycans, and a weaker expression of 
core 1 O-glycans, compared to tumors without recurrence. These 
data seem to indicate a less active or expressed core 1 synthase in 
tumors with recurrence, compared to tumors without recurrence. 
This result could, at least partially, explain the higher expression 
of sialyl Tn antigens in tumors with recurrence.
A generally higher level of expression of sialyl T and disialyl T 
antigens was also observed in tumors with recurrence, compared 
to tumors without recurrence, although these differences were 
not significant. Sialylation of the T antigen is governed by action 
of ST6GalNAc-II, and an overexpression of its mRNA level has 
been correlated to poor patient survival in CRC with lymph node 
metastases (45). The incomplete elongation of O-glycans resulting 
in the abundance of these sialylated truncated structures in tumors 
with recurrence may have different origins. Epigenetic silencing 
of glycosyltransferase genes necessary for the synthesis of more 
complex O-glycan core structures may, for instance, be involved, 
for some of related enzymatic activities are known to be signifi-
cantly decreased in cancers (20, 46) Down regulation of the genes 
encoding core 1 enzyme and/or its chaperon Cosmc may also lead 
to the appearance of Tn and sialyl Tn antigens (47, 48). Hypoxia-
induced transcription modification of several glycosyltransferase 
genes may also be involved in advanced tumoral stage (49).
In this work, we compared the pattern of glycosylation of 
mucins from three tumors with recurrence and six tumors 
without recurrence. Even if numbers of cases were relatively 
FigUre 3 | comparison of the relative abundance of major mucin O-glycans purified from tumors of stage ii (n = 4), stage iii (n = 3), or stage iV 
(n = 3). A low increase in the level of expression of ions at m/z 534, 691, and 983 was observed in stage IV colorectal tumors, compared to stages II and III.
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small, the most striking feature of O-glycans from tumors with 
recurrence, compared to tumors without recurrence, concerned 
the balance between the level of expression of core  1- and 
core 3-based glycans. In tumors without recurrence, a strong 
decrease in core 3-based O-glycans, correlated to a high increase 
in core 1-based O-glycans, was observed. By contrast, in 
tumors with recurrence, the level of expression of core 3-based 
oligosaccharides remains important and only a slight increase 
in the proportion of core 1 O-glycans can be seen. Compared 
to healthy controls, the profile of glycosylation of mucins from 
tumors with recurrence is less altered than the one of tumors 
without recurrence. In other words, mucin O-glycosylation 
from tumors with recurrence looks at least partially like the one 
of healthy controls. The high proportion of core 3 O-glycans in 
tumors with recurrence may contribute to mimic normal physi-
ological conditions, rendering the immune defense system less 
efficient to fight the tumor cells.
In this study, we also compared the profile of glycosylation of 
mucins between tumors, resection margins, and healthy controls. 
No significant differences in the level of expression of Sda/Cad 
antigens were observed between these three types of samples. 
Previous studies have reported a loss of Sda synthase and Sda 
antigens in colorectal cancers (50–52). Our precedent study on 
glycosylation of MUC2 in three human colorectal carcinomas 
allowed us to demonstrate that the disialylated glycans with Sda/
Cad epitope (corresponding to the ion at m/z 1746) were both 
recovered in normal and cancerous tissues whereas a decrease 
in the monosialylated glycans with Sda/Cad epitopes was found 
(19). This study confirms that mucins from colorectal carcinomas 
still express Sda/Cad antigens. One explanation for the absence 
of differences in the level of expression of these antigens between 
healthy controls and tumors may come from the origin of sam-
ples. Indeed, it has been demonstrated that Sda/Cad antigens are 
mainly expressed in the descending colon (29, 53) and results are 
presented here as the mean of percentage of each oligosaccharide 
for all samples from the same condition. Taken individually, 
results showed great differences in the level of expression of these 
antigens (data not shown).
Comparison of glycosylation between tumors, resection 
margins, and healthy controls indicate the presence of gradients 
of expression of major O-glycans: core 3 O-glycans decreased 
from healthy controls to tumors, and an increasing gradient 
of core 1 O-glycans was recovered. This result probably arises 
from alterations in the level of expression of genes encoding 
glycosyltransferases or in the activities of such enzymes. Previous 
studies have demonstrated, by quantitative real time RT-PCR, an 
overexpression of C1GALT1 in tumors of patients with colorectal 
cancer, promoting the invasive behavior of tumoral cells (22, 54). 
Other studies, using quantitative real time PCR and immunohis-
tochemistry have shown a downregulation of core 3 synthase in 
carcinomas (24).
Comparison of the glycosylation patterns of mucins from 
resection margins and healthy controls shows that alterations of 
mucin O-glycans are not only recovered in tumors but also in 
resection margins. This suggests that, even if margins of resection 
are macroscopically and anatomically safe, molecular alterations 
are nevertheless present and may contribute to the risk of recur-
rence for certain patients.
In this study, no correlation was established between mucin 
O-glycans and the stage of colorectal cancers. Variations in the 
level of expression of certain glycans have been observed, such as 
a higher expression of ions at m/z 534 (T antigen), 691 (sialyl Tn 
antigen), and 983 in stage IV. However, none of these alterations 
were significant. Even if numbers of samples in each stage was 
relatively low, one hypothesis may be that modifications of mucin 
glycosylation are an early step during colorectal carcinogenesis.
A
B
FigUre 4 | comparison of the glycosylation pattern of mucins 
purified from colorectal tumors with or without recurrence. MALDI-MS 
spectra, acquired in the positive ion mode [M + Na]+ (or [M + 2Na-H]+ for 
sulfated species), of human intestinal permethylated O-glycans from mucins 
purified from (a) tumors with recurrence; (B) tumors without recurrence. 
Monosaccharide symbols according to the Consortium for Functional 
Glycomics (CFG) nomenclature. Key: fucose (red triangle), GlcNAc (blue 
square), sialic acid (purple diamond), galactose (yellow circle), GalNAcol 
(yellow square), and sulfate residue (S).
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FigUre 5 | comparison of the relative abundance of major mucin O-glycans between healthy controls (n = 5), tumors with recurrence (n = 3), and 
tumors without recurrence (n = 6). The mean is represented for all measurements. A decrease in the level of expression of core 3-based glycans from healthy 
controls to tumors without recurrence is seen with the ions at m/z 936, 1,140, and 1,314 and an increase in the core 1-based glycans is represented by the ions at 
m/z 534, 983, 1,157, and 1,344. Tumors with recurrence expressed higher levels of sialyl Tn (ion at m/z 691), sialyl T (ion at m/z 895), and disialyl T antigens (ion at 
m/z 1,256), compared to healthy controls and tumors without recurrence.
In conclusion, our work demonstrated for the first time a 
possible correlation between mucin O-glycosylation patterns in 
the resected tumor of patients and the risk of recurrence. These 
findings might prove valuable as prognostic tools orienting the 
cure to be given to patients after resection.
Materials and Methods
human samples and Mucin Preparation
Fresh tissue samples from 10 individuals with colorectal carci-
noma were taken at surgery. Specimens were obtained from the 
tumor as well as from resection margins. A summary of localiza-
tion of tissue sampling, tumor stage, grade of differentiation, age, 
and sex of the donors is given in Table 1. Colorectal tissues from 
five healthy individuals were also included in this study. These 
samples were healthy resection margins of colonic tissues arising 
from patients with diverticulosis. The use of human tissues for 
this study was approved by the local hospital ethics committee 
and French Ministry of Higher Education and Research (DC-
2008-242). All subjects gave written informed consent in accord-
ance with the Declaration of Helsinki.
Samples were frozen and stored at −20°C until used. A 
pathologist at the Saint Vincent Hospital of Lille carried out 
the CRC diagnosis of tumors. All samples were obtained with 
informed consent of the patients.
isolation and Purification of Mucins from 
colorectal Tissues
Mucins were solubilized in 4 M guanidine chloride solution con-
taining 10 mM dithiothreitol, 5 mM ethylenediaminetetraacetic 
acid, 10 mM benzamidine, 5 mM N-ethylmaleimide, 0.1 mg/mL 
soy bean trypsin inhibitor, and 1  mM phenylmethanesulfonyl 
fluoride.
Cesium chloride was added to an initial density of 1.4 g/mL 
and mucins were purified by isopycnic density-gradient centrifu-
gation (Beckman Coulter LE80K ultracentrifuge; 70.1 Ti rotor, 
417 600  g at 15°C for 72  h). Fractions of 1  mL were collected 
from the bottom of the tube and analyzed for periodic acid-Schiff 
(PAS) reactivity and density. The mucin-containing fractions 
were pooled, dialyzed against water, and lyophilized.
release of Oligosaccharides from Mucin by 
alkaline Borohydride Treatment
The intestinal mucins were submitted to β-elimination under 
reductive conditions (0.1 M KOH, 1 M KBH4 for 24 h at 45°C). 
The mixture of oligosaccharides alditols was purified by size 
exclusion chromatography on a column of Bio-Gel P2 (85 cm × 
2 cm ID, 400 mesh, Bio-Rad, Richmond, CA, USA) equilibrated 
and eluted with water (10 mL/h) at room temperature. The oligo-
saccharide fractions, detected by UV absorption at 206 nm, were 
pooled for structural analysis.
Permethylation and Mucin glycosylation 
analysis by MalDi-TOF Mass spectrometry
Permethylation of the mixture of oligosaccharide alditols was 
carried out with the sodium hydroxide procedure described 
by Ciucanu and Kerek (55). After derivatization, the reaction 
products were dissolved in 200 μL of methanol and further 
purified on a C18 Sep-Pak column (Waters, Milford, MA, 
USA). Permethylated oligosaccharides were analyzed by 
MALDI-TOF MS in positive ion reflective mode as [M + Na]+. 
Quantification through the relative percentage of each 
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